載入中
NASDAQHealthcareBiotechnology
最新資料
US$16.54
−US$0.01 · -0.06%
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
一般交易時段
US$16.4768
−US$0.0732 · -0.44%
盤中時間採用ET。市場資料可能有所延遲。
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
日內區間
目前US$16.4768
52週區間
目前US$16.4768
盤中時間採用ET。市場資料可能有所延遲。
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
日內區間
目前US$16.4768
52週區間
目前US$16.4768
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.83億 USD | 2.35億 USD | 1.76億 USD | 1.34億 USD | 4560.5萬 USD |
| 銷貨成本 | 3266.5萬 USD | 2824.8萬 USD | 1414.8萬 USD | 566.4萬 USD | 109.1萬 USD |
| 毛利 | 2.5億 USD | 2.07億 USD | 1.61億 USD | 1.28億 USD | 4451.4萬 USD |
| 研究與開發 | 3250.5萬 USD | 2078.5萬 USD | 4964.1萬 USD | 4498.8萬 USD | 5113.9萬 USD |
| 銷售、一般及管理費用 | 1.02億 USD | 1.72億 USD | 1.95億 USD | 1.96億 USD | 1.71億 USD |
| 營業費用 | 1.45億 USD | 2.12億 USD | 2.53億 USD | 2.4億 USD | 2.25億 USD |
| 利息收入 | 1357.3萬 USD | 1697萬 USD | 1699.7萬 USD | 511.8萬 USD | 52.9萬 USD |
| 利息支出 | 433萬 USD | 483.5萬 USD | 277.5萬 USD | — | — |
| 折舊和攤銷 | 927萬 USD | 1944.5萬 USD | 1164.7萬 USD | 270.6萬 USD | 276.1萬 USD |
| 營業利益 | 1.05億 USD | −468.7萬 USD | −9169.1萬 USD | −1.11億 USD | −1.81億 USD |
| 淨利 | 2.87億 USD | 575.2萬 USD | −7802萬 USD | −1.08億 USD | −1.81億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$16.00
下跌空間 2.89%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2013年10月23日 | 1:50 | — | — |
已生效 2013年10月23日
1:50
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM5063.88萬0.07%787.4億 USD0.19%US$276.45-0.52%
iShares Russell 2000 Growth ETFIWO1824.75萬0.13%139.17億 USD0.24%US$351.05-0.75%
iShares Biotechnology ETFIBB1517.33萬0.14%108.2億 USD0.44%US$201.56-1.32%
Vanguard Russell 2000 ETFVTWO1104.37萬0.06%180億 USD0.06%US$111.66-0.55%
Fidelity Enhanced Small Cap ETFFESM770.68萬0.12%64.1億 USD0.28%US$45.04-0.44%
Vanguard Health Care ETFVHT506.04萬0.02%220億 USD0.09%US$317.09-1.12%
Principal U.S. Small-Cap Multi-Factor ETFPSC395.76萬0.14%27億 USD0.38%US$67.56-0.18%
Avantis U.S. Small Cap Equity ETFAVSC314.42萬0.10%30.79億 USD0.25%US$69.86-0.16%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTPrincipal U.S. Small-Cap Multi-Factor ETFPSCAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
